Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer
NCT00536939
Terminated
The purpose of this study is to determine efficacy and safety of paclitaxel, bevacizumab and enzastaurin versus paclitaxel, bevacizumab, and placebo in participants who are diagnosed with locally recurrent or metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/23/2020
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Newark, Delaware +6 locations
Conditions: Breast Cancer
Register for Updates
PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer
NCT01697293
Terminated
This phase I/II trial studies the side effects and the best dose of triciribine phosphate when given together with paclitaxel, doxorubicin hydrochloride, and cyclophosphamide and to see how well they work in treating patients with stage IIB-IV breast cancer. Triciribine phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel, doxorubicin hydrochloride, and cyclophosphamide, work in different ways to stop... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/22/2020
Locations: Moffitt Cancer Center, Tampa, Florida +1 locations
Conditions: Breast Adenocarcinoma, Estrogen Receptor Positive, HER2/Neu Negative, Recurrent Breast Carcinoma, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Register for Updates
Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy
NCT00574587
Completed
Vorinostat is a histone deacetylase (HDAC) inhibitor which is approved by the U.S. Food and Drug Administration for the treatment of a rare type of cancer involving the skin (cutaneous T cell lymphoma), but not for breast cancer. HDAC inhibitors work by unsilencing tumor suppressor genes and other genes in the cancer cells that are repressed; when the genes are turned back on by the drug, it leads to death of the cancer cells. HDAC inhibitors such as vorinostat have been shown to enhance the eff... Read More
Gender:
FEMALE
Ages:
Between 18 years and 100 years
Trial Updated:
09/18/2020
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Breast Cancer
Register for Updates
Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function
NCT00478361
Completed
This phase II trial is studying how well giving gemcitabine, paclitaxel, and doxorubicin together with pegfilgrastim works in treating patients with metastatic or unresectable bladder cancer or urinary tract cancer and kidney dysfunction. Drugs used in chemotherapy, such as gemcitabine, paclitaxel, and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Colony stimulating factors, such as pegfilgrastim, may increas... Read More
Gender:
ALL
Ages:
All
Trial Updated:
09/17/2020
Locations: Ozark Health Ventures LLC dba Cancer Research for The Ozarks Springfield, Springfield, Missouri +1 locations
Conditions: Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter, Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder, Urethral Cancer Associated With Invasive Bladder Cancer
Register for Updates
Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer
NCT00226746
Withdrawn
The purpose of this study is to find out what effects, good and bad, the chemotherapy drugs gemcitabine (Gemzar) and paclitaxel (Taxol) have in combination with twice daily radiation treatment on locally advanced pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/16/2020
Locations: New York Methodist Hospital, Brooklyn, New York
Conditions: Carcinoma, Pancreatic Ductal
Register for Updates
Single Arm on the Tolerability of Weekly Nab-paclitaxel
NCT01702844
Completed
The purpose of this study is to evaluate the safety and efficacy of weekly nab-paclitaxel for a second-line treatment in elderly subjects, 70 years of age or greater, with non-small cell lung cancer (NSCLC)
Gender:
ALL
Ages:
70 years and above
Trial Updated:
09/14/2020
Locations: Highlands Oncology Group, Fayetteville, Arkansas +7 locations
Conditions: Non Small Cell Lung Cancer (NSCLC)
Register for Updates
Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer
NCT00014222
Completed
RATIONALE: 1. . To compare the effects on breast cancer of three different combinations of drugs which are commonly used to treat this disease. 2. . It is not yet known which treatment regimen is most effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy given with or without epoetin alfa in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer.
Gender:
FEMALE
Ages:
60 years and below
Trial Updated:
09/11/2020
Locations: Sparks-Arkansas Oklahoma Cancer Treatment Centre, Fort Smith, Arkansas +77 locations
Conditions: Breast Cancer
Register for Updates
A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer
NCT01616303
Completed
This is a Phase 2 randomized study with two treatment arms to compare the effectiveness of oregovomab (a murine monoclonal antibody directed against cancer antigen 125 (CA125)) when combined with first-line chemotherapy (carboplatin and paclitaxel) to first-line chemotherapy (carboplatin and paclitaxel alone) in female patients with advanced ovarian cancer.
Gender:
FEMALE
Ages:
Between 18 years and 75 years
Trial Updated:
09/11/2020
Locations: University of Connecticut Health Center, Farmington, Connecticut +1 locations
Conditions: Ovarian Neoplasms
Register for Updates
A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
NCT01649336
Completed
This is a Phase 1 study during which patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer will receive investigational study drug MEK162 and paclitaxel. Patients will receive increasing doses of study drug in combination with paclitaxel in order to achieve the highest dose of study drug possible that will not cause unacceptable side effects. Patients will be followed to see what side effects the combination causes and what effectiveness the combination... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/09/2020
Locations: Pfizer Investigational Site, Scottsdale, Arizona +3 locations
Conditions: Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Register for Updates
Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer
NCT01566435
Completed
This phase II trial studies the safety and effectiveness of an induction chemotherapy (ACF) consisting of paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel), cisplatin and fluorouracil followed by chemoradiation therapy in treating patients with stage III-IV squamous cell cancer of the head and neck. ACF may be an effective way to reduce or downgrade locally aggressive tumors, and improve the chance of eradication by chemoradiation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/09/2020
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Head and Neck Neoplasms
Register for Updates
Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.
NCT00367471
Completed
The purpose of this study is to determine the optimally-tolerated regimens (OTR) for lapatinib in combination with paclitaxel, carboplatin with and without trastuzumab in patients with metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/08/2020
Locations: Novartis Investigative Site, La Jolla, California +2 locations
Conditions: Neoplasms, Breast
Register for Updates
Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
NCT02050178
Completed
This is an open-label Phase 1b dose-escalation study to assess the safety, tolerability, and PK of OMP-54F28 when combined with nab-paclitaxel and gemcitabine. OMP-54F28 will be administered IV on Days 1 and 15 of each 28-day cycle. Nab-paclitaxel (125 mg/m2) and gemcitabine (1000 mg/m2) will be administered IV on Days 1, 8, and 15 of each cycle. The planned dose levels of OMP-54F28 are 3.5 mg/kg and 7.0 mg/kg.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
09/07/2020
Locations: USC/Norris Comprehensive Cancer Center, Los Angeles, California +4 locations
Conditions: Pancreatic Cancer, Stage IV Pancreatic Cancer
Register for Updates